Gail Naughton - CR Bard Independent Director

Director

Dr. Gail K. Naughton, Ph.D. is Independent Director of the Company. She is Chairman and Chief Executive Officer of Histogen, Inc. . Dr. Naughton has served as the Chairman and Chief Executive Officer of Histogen, Inc. since June 2007, having been Vice Chairman of Advanced Tissue Sciences, Inc. from March 2002 to October 2002, President from August 2000 to March 2002, President and Chief Operating Officer from 1995 to 2000 and CoFounder and Director since inception in 1991. Dr. Naughton also served as Dean of the College of Business Administration at San Diego State University from August 2002 to June 2011. She is also a director of Cytori Therapeutics, Inc. Dr. Naughton was nominated to serve an additional term as a director because of the breadth of her life sciences industry knowledge and experience, including her experience as Chairman and Chief Executive Officer of Histogen, Inc. Dr. Naughton was the first woman to be awarded the National Inventor of the Year award by The Intellectual Property Owners Association. She has conducted extensive research, authored numerous scientific publications and holds more than 95 U.S. and foreign patents. Dr. Naughton has also built a distinguished academic career, including serving as the Dean of the College of Business Administration, San Diego State University and on the boards of several academic institutions, nonprofit organizations and foundations since 2004.
Age 60
Tenure 20 years
Professional MarksMBA
Phone908 277-8000
Webwww.crbard.com
Naughton earned a B.S. from St. Francis College, Brooklyn, New York, and both an M.S. in Histology and a Ph.D. in Hematology from New York University Medical Center. She also holds an M.B.A. in Executive Management from the Anderson School at the University of California, Los Angeles.

CR Bard Management Efficiency

CR Bard's management efficiency ratios could be used to measure how well CR Bard manages its routine affairs as well as how well it operates its assets and liabilities.
The company has 1.64 B in debt with debt to equity (D/E) ratio of 81.4, demonstrating that the company may be unable to create cash to meet all of its financial commitments. CR Bard has a current ratio of 1.69, which is typical for the industry and considered as normal. Debt can assist CR Bard until it has trouble settling it off, either with new capital or with free cash flow. So, CR Bard's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CR Bard sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BCR to invest in growth at high rates of return. When we think about CR Bard's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Brenda FreemanBrp Group
53
Kyle SkogmanUnited Fire Group
67
Virginia HepnerNational Vision Holdings
60
Susan VossUnited Fire Group
62
John HolderGenuine Parts Co
66
Gary FayardGenuine Parts Co
69
Peter BrowningGMS Inc
79
Dennis ClementsAsbury Automotive Group
73
Brian HoestereyGMS Inc
51
Mary BullockGenuine Parts Co
70
Brenda ClancyUnited Fire Group
63
Jenner WoodGenuine Parts Co
66
Steven KornBrp Group
63
Theron GilliamGMS Inc
56
Edward WaryasKNOT Offshore Partners
72
Takuji BannoKNOT Offshore Partners
N/A
Ronald RossGMS Inc
66
John JohnsGenuine Parts Co
69
Yoshiyuki KonumaKNOT Offshore Partners
52
Gary RollinsGenuine Parts Co
70
Philip MaritzAsbury Automotive Group
60
C. R. Bard, Inc., together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. CR Bard (BCR) is traded on New York Stock Exchange in USA and employs 14,900 people.

Management Performance

CR Bard Leadership Team

Elected by the shareholders, the CR Bard's board of directors comprises two types of representatives: CR Bard inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BCR. The board's role is to monitor CR Bard's management team and ensure that shareholders' interests are well served. CR Bard's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CR Bard's outside directors are responsible for providing unbiased perspectives on the board's policies.
James Beasley, Group President
Patricia Christian, Vice President - Quality, Regulatory and Medical Affairs
Sharon Alterio, Group Vice President
Todd Garner, Vice President - Investor Relations
Marc Breslawsky, Independent Director
John Weiland, President, COO and Director
John DeFord, Senior Vice President - Science, Technology and Clinical Affairs
Frank Lupisella, Principal Accounting Officer, VP and Controller
Betty Larson, Vice President Human Resources.
John Groetelaars, Group Vice President
Tony White, Independent Director
Gerard Porreca, Vice President - Quality, Regulatory and Medical Affairs
Robert Davis, Director
Anthony Welters, Independent Director
Gail Naughton, Independent Director
John Kelly, Independent Director
Tommy Thompson, Independent Director
Samrat Khichi, Senior Vice President General Counsel, Secretary
Sharon Luboff, Group Vice President
Herbert Henkel, Lead Independent Director
Christopher Holland, CFO and Sr. VP
David Melcher, Director
Jim Beasley, Group Pres
Timothy Collins, Group Pres
Timothy Ring, Chairman, CEO and Chairman of Executive Committee
David Barrett, Independent Director

BCR Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CR Bard a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with CR Bard

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CR Bard position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CR Bard will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Note that the CR Bard information on this page should be used as a complementary analysis to other CR Bard's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Other Consideration for investing in BCR Stock

If you are still planning to invest in CR Bard check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CR Bard's history and understand the potential risks before investing.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Equity Valuation
Check real value of public entities based on technical and fundamental data